Ruhvenile is a drug discovery company and it offers the drug development services based on structure-based drug design in silico, including docking molecular, drug target identification, drug discovery screening – small molecule screening, library screening, ion channel screening – fragment-based drug design, ligand-based drug design, ligand-protein binding, protein-ligand docking calculation and prediction, drug profiling, lead identification, lead compound identification and lead optimization.
Many biotech companies in India as well as in the USA are pursuing anticancer drug discovery projects, of which over half are concentrated on cancer drug development and cancer treatment. Ruhvenile offers drug-like lead compounds, chemical compound libraries including screening compounds: small molecules, natural compounds as well as diversity libraries, custom libraries, e.g. angiogenesis inhibitors, gpcr library, kinase library, kinase inhibitor library.
Ruhvenile drug design consultancy helps the scientists in their anticancer drug development efforts on tumor regression and an identification of new drugs targets and drug candidates.